Finanzen von Annovis Bio Inc (ANVS)ANVSAnnovis Bio Inc

Evaluating the bottom line, Annovis Bio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -703.68%, provide a clear picture of how effectively ANVS converts its operational activities into shareholder value.

In the context of the broader market, ANVS competes directly with industry leaders such as CTOR and RNXT. With a market capitalization of $78.82M, it holds a significant position in the sector. When comparing efficiency, ANVS's gross margin of N/A stands against CTOR's 67.07% and RNXT's 84.27%. Such benchmarking helps identify whether Annovis Bio Inc is trading at a premium or discount relative to its financial performance.

Annovis has been experiencing substantial losses, with a net income of -17606382 USD in Q1 2026 and a forward P/E ratio of 0, indicating no earnings expected in the near future.